[Chemotherapy for early breast cancer: practices in 2010].
The management of breast cancer has changed at both surgery levels, with the development of sentinel node, and at the medical level with the use of new therapies. Breast cancer is a heterogeneous disease and each patient should be offered an adapted treatment in an effort to reduce the risk of relapse and death, with the minimal toxicities. The micrometastatic disease appears early in the history of the tumor and chemotherapy aims to eradicate it. In this review, we describe the state of practice regarding adjuvant and neoadjuvant chemotherapy for early breast cancer.
Service d'oncologie médicale, centre de lutte contre le cancer René-Gauducheau, institut de cancérologie de Nantes-Atlantique, boulevard Jacques-Monod, 44805 Nantes-Saint-Herblain, France. js-frenel@nantes.fnclcc.fr
J-S
JS
Frénel
M
M
Campone
D018943:Anthracyclines / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant / Q000639:trends; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D020360:Neoadjuvant Therapy / Q000639:trends; D043823:Taxoids / Q000627:therapeutic use; D000068878:Trastuzumab
D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D043823:Taxoids; D003520:Cyclophosphamide; D000068878:Trastuzumab; D005472:Fluorouracil